Role of ‘Aviptadil’ in Treatment of Acute Respiratory Distress Syndrome (ARDS): Case Series
Keywords:
Acute viral illness, Acute lung injury, ARDS, Acute Respiratory Distress Syndrome, Cytokines, Lung alveolar cells type II, Surfactant replacement, Vasoactive intestinal peptide (Aviptadil)Abstract
As we know respiratory failure is a lethal complication of viral illnesses that has remained resistant to conventional treatment and ventilator support. Acute respiratory distress syndrome is life-threatening scenario that requires ICU admissions. Treating this condition requires proper oxygenation strategies with mechanical ventilation and positive pressure (PEEP) to recruit alveoli. Vasoactive intestinal peptide (Aviptadil) is shown in literature to up regulate surfactant production, inhibit cytokine synthesis, prevent cytopathic effects and block replication of viral cells in pulmonary cells. Human vasoactive intestinal peptide prevents further lung injury and reduces inflammation. We share our observation and experience via this case series regarding effective and safe use of aviptadil for treating ARDS arising from viral illnesses and others apart from its previous benefits found in COVID19 related ARDS cases.
How to cite this article:
Gupta S, Deshpande S, Raul K, Pramanik
V, Navpute K, Solanke O. Role of ‘Aviptadil’
in Treatment of Acute Respiratory Distress
Syndrome (ARDS): Case Series. J Adv Res Med
Sci Tech. 2025;12(1&2):15-21.
DOI: https://doi.org/10.24321/2394.6539.202503
References
Nanda C, Mehta C, Mehta Y, Joshi S, Bhan A, Bhan A. Aviptadil as a Promising Intervention: A Case Study for Transfusion-Related Acute Lung Injury Treatment in a Cardiac Patient. Journal of Cardiothoracic and Vascular Anesthesia. 2024 May 1;38(5):1276-9.
Youssef JG, Lavin P, Schoenfeld DA, Lee RA, Lenhardt R, Park DJ, Fernandez JP, Morganroth ML, Javitt JC, Jayaweera D. The use of IV vasoactive intestinal peptide (Aviptadil) in patients with critical COVID-19 respiratory failure: results of a 60-day randomized controlled trial. Critical care medicine. 2022 Nov 1;50(11):1545-54.
Mehta Y, Mehta C, Chandrasekaran A. Aviptadil: A multifaceted approach to mitigating hypoxemia in acute respiratory distress syndrome. Respiratory Medicine Case Reports. 2024 Jan 1;48:101992.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Sagar Gupta , Sudhir Deshpande, Kuldeepsing Raul, Vishram Pramanik, Kapil Navpute, Omprakash Solanke
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
